CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?

The T cells are genetically modified to expressa chimeric antigen receptor targeting BCMA andare infused after induction therapy at a target dose of ≥2.0×10\^6 cells/kg

Patients in this arm will receive autologous hematopoietic stem cell transplantation (ASCT).